New York’s leading experts in Alzheimer’s disease (AD) and dementia care, formerly known as the Alzheimer’s Association, New York City Chapter, have unveiled their new name, CaringKind: The Heart of Alzheimer’s Caregiving. The New York City chapter broke away from the national organization in December and is now…
Takeda Pharmaceutical Company and partner Zinfandel Pharmaceuticals announced the completion of patient enrollment in the TOMMORROW Phase 3 Clinical Trial, one of the largest studies ever to be executed in mild cognitive impairment and Alzheimer’s disease (AD). Previous research has shown that individuals who develop mild cognitive impairment (MCI) are…
A critical but vulnerable brain region seems to be the first area disturbed by late onset Alzheimer’s disease, and to be a region more essential for preserving cognitive function in later life than previously thought, according to a review, “The Locus Coeruleus: Essential for Maintaining Cognitive…
Scientists have discovered the anti-cancer drug bexarotene may target the first step in the toxic chain activity that leads to the death of brain cells, paving the way to new Alzheimer’s therapies. The study, conducted by an international team of researchers from the University of Cambridge in England, Lund University in…
As part of Allianz Championship week in Boca Raton, Florida, Allianz encouraged golf enthusiasts to share their favorite golf memories on Facebook, Twitter, Instagram and other social media sites — using the hashtag #AllianzBirdies — to raise awareness of the Alzheimer’s Association and its work. Two company groups — Allianz Life and Allianz Global…
Tarrytown, New York-based PsychoGenics has announced its Line-41 mouse model of Alzheimer’s disease (AD) has obtained a license from the University of California, San Diego. This experimental model expresses human APP with the London (V717I) and Swedish (K670N/M671L) mutations under the murine-Thy-1 promoter control. PsychoGenics is a leader in providing preclinical…
A National Football League broadcaster and former NFL player is urging Americans to “Huddle Up for New Alzheimer’s Treatments” by participating in clinical trials testing new drugs that may potentially treat the degenerative brain disease. The new educational and awareness-raising campaign teams Solomon Wilcots with Axovant Sciences, Ltd., and patient advocacy groups in…
Lack of sleep on a regular basis or waking up several times during the night may be harmful to the brain and increase the risk of developing Alzheimer’s disease, according to recent evidence. Patients with Alzheimer’s disease tend to sleep poorly and stay awake more often at night. However, researchers have…
PsychoGenics Inc. and the Alzheimer’s Drug Discovery Foundation (ADDF) announced a collaboration that opens PsychoGenics’ Alzheimer’s animal models and investigational services to recipients of ADDF grants who are working in preclinical Alzheimer’s drug discovery programs. Through the collabortion, PsychoGenics will offer its products and services to ADDF-funded biotechnology companies on “extremely favorable…
Evotec AG has reached an important milestone concerning its TargetAD partnership with Janssen Pharmaceuticals for the transition of a product into further drug discovery process. Even though the announcement was made this year, the milestone was reached in 2015. Evotec’s TargetAD database is a customized system to provide unique information on the connection between molecular…
Get regular updates to your inbox.